Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
SI

NASDAQ · SIGA

SIGA Technologies, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$3.04

Down-$0.14 (-4.40%)

Updated Nov 1, 2026, 11:31 PM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
467.61M
P/E ratio
5.68
Dividend yield
19.74%
52-week range
$2.83 – $5.79
Volume
504.68K
Avg. volume
415.38K

Price performance · SIGA

SIGA price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

SIGA closed at $3.04 after 20 trading sessions, down 12.64% for the selected period.

Last close
$3.04
Period change
-12.64%
Period low
$3.04
Period high
$3.48
Daily close
View OHLC price history
SIGA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$3.18$3.24$3.03$3.04504.68K
Oct 29, 2026$3.32$3.3275$3.07$3.18495K
Oct 28, 2026$3.24$3.32$3.19$3.31759.41K
Oct 27, 2026$3.16$3.235$3.14$3.20409.26K
Oct 26, 2026$3.11$3.20$3.10$3.155378.74K
Oct 23, 2026$3.13$3.15$3.04$3.12476.24K
Oct 22, 2026$3.12$3.175$3.12$3.15202.56K
Oct 21, 2026$3.15$3.18$3.12$3.12267.55K
Oct 20, 2026$3.15$3.22$3.12$3.15321.21K
Oct 19, 2026$3.16$3.19$3.13$3.14397.48K
Oct 16, 2026$3.19$3.20$3.07$3.17909.07K
Oct 15, 2026$3.13$3.265$3.11$3.19711.1K
Oct 14, 2026$3.06$3.115$3.035$3.10331.17K
Oct 13, 2026$3.16$3.19$3.08$3.08293.52K
Oct 12, 2026$3.27$3.276$3.15$3.16322.52K
Oct 9, 2026$3.28$3.3591$3.2612$3.28464.98K
Oct 8, 2026$3.23$3.33$3.15$3.28676.28K
Oct 7, 2026$3.27$3.345$3.24$3.26428.9K
Oct 6, 2026$3.48$3.485$3.23$3.29795.04K
Oct 5, 2026$3.40$3.675$3.40$3.48964.03K

Latest SIGA news

The latest Smart Investors Daily articles mentioning SIGA.

Stock researchCompany · Overview

SIGA research

Overview

Company profile and research snapshot.

Company profile

SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

SIGA Secures Contract Valued at Up to $15 Million from Canadian Department of National Defence to Purchase TPOXX®

Continues Canada's commitment to smallpox preparedness for the Canadian Armed ForcesNEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that Public Services and Procurement Canada (PSPC) has awarded SIGA a new contract for the procurement of oral TPOXX® (tecovirimat), an antiviral medication used to treat smallpox, on behalf of the Canadian Department of National Defence (CDND) through its Strategic

Benzinga · Oct 12, 2026

Full Transcript: SIGA Technologies Q2 2026 Earnings Call

SIGA Technologies (NASDAQ:SIGA) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and

Yahoo · Sep 6, 2026

SIGA Tech (SIGA): Profits Drop 65%, But Cash and Special Payouts Remain

On August 6, SIGA Technologies (NASDAQ:SIGA) reported financial results for the three and six months ended June 30, and the numbers tell two very different stories depending on which quarter you compare them to. Revenue and profit both cratered from a year ago, yet the company still turned a profit, paid out a special dividend, […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By